An exploratory double‐blind, randomized clinical trial with selisistat, a <scp>SirT1</scp> inhibitor, in patients with <scp>H</scp>untington's disease

Abstract

Selisistat was found to be safe and well tolerated in early stage HD patients at plasma concentrations within the anticipated therapeutic concentration range.